FDA Approves Pembrolizumab for Metastatic SCLC
June 18, 2019 - The FDA has granted an accelerated approval to single-agent pembrolizumab for the treatment of patients with metastatic small cell lung cancer (SCLC) who have disease progression on or after platinum-based chemotherapy and ≥1 other prior line of therapy. ...Leggi tutto